These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

426 related articles for article (PubMed ID: 29614779)

  • 81. Tryptophan 375 stabilizes the outer-domain core of gp120 for HIV vaccine immunogen design.
    Hu D; Bowder D; Wei W; Thompson J; Wilson MA; Xiang SH
    Vaccine; 2017 May; 35(23):3067-3075. PubMed ID: 28461065
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Subtype C gp140 Vaccine Boosts Immune Responses Primed by the South African AIDS Vaccine Initiative DNA-C2 and MVA-C HIV Vaccines after More than a 2-Year Gap.
    Gray GE; Mayer KH; Elizaga ML; Bekker LG; Allen M; Morris L; Montefiori D; De Rosa SC; Sato A; Gu N; Tomaras GD; Tucker T; Barnett SW; Mkhize NN; Shen X; Downing K; Williamson C; Pensiero M; Corey L; Williamson AL
    Clin Vaccine Immunol; 2016 Jun; 23(6):496-506. PubMed ID: 27098021
    [TBL] [Abstract][Full Text] [Related]  

  • 83. A shot at AIDS.
    Koff WC
    Curr Opin Biotechnol; 2016 Dec; 42():147-151. PubMed ID: 27153215
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Targeting B-cell germlines and focusing affinity maturation: the next hurdles in HIV-1-vaccine development?
    Medina-Ramírez M; Sanders RW; Klasse PJ
    Expert Rev Vaccines; 2014 Apr; 13(4):449-52. PubMed ID: 24606603
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Regulatory T cell abundance and activation status before and after priming with HIVIS-DNA and boosting with MVA-HIV/rgp140/GLA-AF may impact the magnitude of the vaccine-induced immune responses.
    Chissumba RM; Luciano A; Namalango E; Bauer A; Bhatt N; Wahren B; Nilsson C; Geldmacher C; Scarlatti G; Jani I; Kestens L;
    Immunobiology; 2018 Dec; 223(12):792-801. PubMed ID: 30121146
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Report of the Cent Gardes HIV Vaccine Conference: The B-cell Response to HIV. Part 1: Broadly Neutralizing Antibodies Fondation Mérieux Conference Center, Veyrier du Lac, France, 5-7 November 2012.
    Girard MP; Picot V; Longuet C; Nabel GJ
    Vaccine; 2013 Jun; 31(29):2979-83. PubMed ID: 23499518
    [TBL] [Abstract][Full Text] [Related]  

  • 87. The RV144 Thai HIV vaccine trial.
    Plotkin SA
    Hum Vaccin; 2010 Feb; 6(2):159. PubMed ID: 20431337
    [No Abstract]   [Full Text] [Related]  

  • 88. Rationally Designed Immunogens Targeting HIV-1 gp120 V1V2 Induce Distinct Conformation-Specific Antibody Responses in Rabbits.
    Jiang X; Totrov M; Li W; Sampson JM; Williams C; Lu H; Wu X; Lu S; Wang S; Zolla-Pazner S; Kong XP
    J Virol; 2016 Dec; 90(24):11007-11019. PubMed ID: 27707920
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Impact of Poxvirus Vector Priming, Protein Coadministration, and Vaccine Intervals on HIV gp120 Vaccine-Elicited Antibody Magnitude and Function in Infant Macaques.
    Phillips B; Fouda GG; Eudailey J; Pollara J; Curtis AD; Kunz E; Dennis M; Shen X; Bay C; Hudgens M; Pickup D; Alam SM; Ardeshir A; Kozlowski PA; Van Rompay KKA; Ferrari G; Moody MA; Permar S; De Paris K
    Clin Vaccine Immunol; 2017 Oct; 24(10):. PubMed ID: 28814388
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Rhesus Macaque B-Cell Responses to an HIV-1 Trimer Vaccine Revealed by Unbiased Longitudinal Repertoire Analysis.
    Dai K; He L; Khan SN; O'Dell S; McKee K; Tran K; Li Y; Sundling C; Morris CD; Mascola JR; Karlsson Hedestam GB; Wyatt RT; Zhu J
    mBio; 2015 Nov; 6(6):e01375-15. PubMed ID: 26530382
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Revisiting the Correlate of Reduced HIV Infection Risk in the Rv144 Vaccine Trial.
    Zolla-Pazner S; Gilbert PB
    J Virol; 2019 Sep; 93(17):. PubMed ID: 31189712
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Passive and active antibody studies in primates to inform HIV vaccines.
    Hessell AJ; Malherbe DC; Haigwood NL
    Expert Rev Vaccines; 2018 Feb; 17(2):127-144. PubMed ID: 29307225
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Insights from HIV-1 vaccine and passive immunization efficacy trials.
    Ahmed S; Herschhorn A
    Trends Mol Med; 2024 Oct; 30(10):908-912. PubMed ID: 38890027
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Reappraising the Value of HIV-1 Vaccine Correlates of Protection Analyses.
    Klasse PJ; Moore JP
    J Virol; 2022 Apr; 96(8):e0003422. PubMed ID: 35384694
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Immune correlates of vaccine protection against HIV-1 acquisition.
    Corey L; Gilbert PB; Tomaras GD; Haynes BF; Pantaleo G; Fauci AS
    Sci Transl Med; 2015 Oct; 7(310):310rv7. PubMed ID: 26491081
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Conference on advances in AIDS vaccine development--1993. Summary: correlates of HIV Immunity Working Group.
    Sheppard H; Bridges SH; Mathieson BJ; Walker MC; Weinhold K
    AIDS Res Hum Retroviruses; 1994; 10 Suppl 2():S171-6. PubMed ID: 7865294
    [No Abstract]   [Full Text] [Related]  

  • 97. Clinical trials and recent progress in HIV vaccine development.
    Zubair A; Bibi B; Habib F; Sujan A; Ali M
    Funct Integr Genomics; 2024 Aug; 24(5):143. PubMed ID: 39192058
    [TBL] [Abstract][Full Text] [Related]  

  • 98. HIV population-level adaptation can rapidly diminish the impact of a partially effective vaccine.
    Herbeck JT; Peebles K; Edlefsen PT; Rolland M; Murphy JT; Gottlieb GS; Abernethy N; Mullins JI; Mittler JE; Goodreau SM
    Vaccine; 2018 Jan; 36(4):514-520. PubMed ID: 29241646
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Is obesity a risk factor for vaccine non-responsiveness?
    Young KM; Gray CM; Bekker LG
    PLoS One; 2013; 8(12):e82779. PubMed ID: 24349359
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Skin side effects stymie advance of HIV vaccine.
    Cohen J
    Science; 2024 Mar; 383(6687):1044. PubMed ID: 38452071
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.